Search the Newsreel

NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill

NewAmsterdam Pharma Stock: Obicetrapib More Than Another LDL-Lowering Pill (NASDAQ:NAMS)

How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story

NewAmsterdam Pharma (NAMS) received a positive CHMP opinion from the EMA for its drugs Ubeslo and Evlarco, recommending EU-wide marketing authorization for primary hypercholesterolemia. This development validates the clinical program and brings the company closer to royalty and milestone economics in Europe through its …

CHMP backs NewAmsterdam Pharma (Nasdaq: NAMS) cholesterol therapies for EU approval

NewAmsterdam Pharma (Nasdaq: NAMS) has received a positive opinion from the European Medicines Agency's CHMP for its cholesterol therapies, Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination). This recommendation, based on strong Phase 3 clinical trial data showing significant LDL-C reductions, is …

Europe's drug committee recommends two NewAmsterdam cholesterol treatments

NewAmsterdam Pharma and Menarini Group received a positive opinion from the European Medicines Agency's CHMP recommending EU marketing authorization for two cholesterol-lowering treatments, Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination). This recommendation is based on positive Phase 3 clinical trial data …

NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26

NewAmsterdam Pharma (NAMS) received a positive CHMP opinion recommending EU marketing authorization for its cholesterol-lowering drugs, Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg + ezetimibe 10 mg). The recommendation is based on strong Phase 3 trial data showing significant LDL-C reductions. A …

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NewAmsterdam Pharma and Menarini Group announced that the CHMP has recommended marketing authorization for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination) for patients with primary hypercholesterolemia. This positive opinion targets a major unmet need for patients unable to reach LDL-C goals …

NewAmsterdam Pharma Company (NAMS) Q1 2026 earnings summary

NewAmsterdam Pharma (NAMS) released its Q1 2026 earnings summary, highlighting its focus on obicetrapib, a CETP inhibitor for LDL-C lowering, with regulatory decisions expected in 2H26. Financials showed $3.0 million in revenue, a net loss of $48.4 million, and $707.3 million in cash reserves. …

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS

The article provides financial information for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), focusing on its enterprise value to revenue forward metric. It appears to be a stub or partial financial data page from TradingView, offering a glimpse into the company's valuation. The content highlights …

NewAmsterdam Pharma's COO Douglas Kling to Leave for CEO Role at Another Clinical-Stage Biotech Company

Douglas Kling, COO of NewAmsterdam Pharma, has announced his resignation effective August 14, 2026, to become CEO at another clinical-stage biotechnology company. The company anticipates negotiating a separation and an advisor agreement with Kling to ensure a smooth transition, particularly for the PREVAIL clinical …

NewAmsterdam Pharma (NAMS) CAO trades 105000 shares under 10b5-1 plan

NewAmsterdam Pharma Co N.V.'s Chief Accounting Officer, Louise Frederika Kooij, exercised options for 105,000 ordinary shares and subsequently sold all of them on July 20, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted on February 23, 2026, involved weighted average prices …

NewAmsterdam Pharma (NAMS) COO Douglas Kling to step down Aug 14

NewAmsterdam Pharma Company N.V. announced that its Chief Operating Officer, Douglas Kling, will resign effective August 14, 2026, to become CEO of another clinical-stage biotech company. Kling notified the company of his decision on July 16, 2026. NewAmsterdam Pharma expects to enter into a …

Jennison Associates LLC Cuts Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Jennison Associates LLC reduced its stake in NewAmsterdam Pharma Company N.V. by 21.2% in the first quarter of 2026, selling 738,818 shares and retaining 2.75 million shares valued at $88 million. Despite this reduction, institutional ownership remains high at 89.89%, with several other firms …

NewAmsterdam Pharma Company (NAMS) Citi Annual Global Healthcare Conference 2025 summary

This summary of NewAmsterdam Pharma's presentation at the Citi Annual Global Healthcare Conference 2025 highlights obicetrapib's strong LDL lowering, Lp(a) reduction, and potential benefits in diabetes risk and Alzheimer's prevention, supported by positive phase 3 trial results. The drug aims to be a primary …

Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data

Jefferies has reiterated a Buy rating and a $45.00 price target for NewAmsterdam Pharma Co NV (NASDAQ:NAMS). The firm anticipates increased volatility for NAMS stock as Novartis's Phase III HORIZON data, which could validate Lp(a) biology, is expected in July or August, though Jefferies …

Responsive Playbooks and the NAMS Inflection

The article analyzes Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting a mid-channel oscillation pattern and a favorable 75.4:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and provides a multi-timeframe signal analysis indicating weak …

NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation

NewAmsterdam Pharma has released a research presentation on the use of its CETP inhibitor, obicetrapib, for Alzheimer's prevention. A Phase 3 substudy showed that obicetrapib reduced plasma p-tau217 after 12 months, particularly in APOE4/E4 carriers, and positively impacted other Alzheimer’s-related biomarkers. This research supports …